A recent study demonstrated that CCL5 contributes to the recruitment of inflammatory cells (mainly T cells and macrophages), and blockading CCR5 signaling using leronlimab (a monoclonal antibody) has been conducted to treat COVID-19-associated cytokine storms (57). The gene discussed is CCR5; the disease is COVID-19.